Identifier matching provides the foundation for organizing drug-target records consistently. Researchers can connect a therapeutic compound with the appropriate protein and then attach details such as mechanism of action, interaction type, and pathway relationships. This structured organization makes it easier to compare compounds, examine shared targets, and interpret how different drugs may influence related biological processes.
Known associations represent drug-target relationships already recorded in the available data, whereas predicted associations extend the map to possible relationships. Keeping these categories distinguishable helps researchers interpret the strength and role of each connection appropriately. In cancer studies, predicted links can broaden target exploration, while known links support analysis of documented pharmacological mechanisms.
Pathway relationships place individual drug-target connections within larger biological systems. A mapped protein may participate in signaling, cell-cycle control, DNA repair, or tumor-survival processes, so examining its pathway context can reveal how drug effects may extend beyond one molecular interaction. This systems-level view supports more informed mechanism-of-action analysis in cancer research.
A basic workflow begins by matching drug identifiers with protein identifiers, followed by organizing the resulting drug-target associations. Researchers can then annotate records with interaction types, mechanisms of action, and related pathways. In a cancer-focused analysis, the organized dataset can be examined for links to signaling, cell-cycle regulation, DNA repair, and tumor-survival biology.
By connecting compounds with their documented or predicted protein targets, the mapping can reveal relationships between a drug and biological processes relevant to cancer. Researchers may use these connections to identify existing compounds whose target profiles fit a different therapeutic question. The resulting associations provide a basis for evaluating repurposing possibilities alongside mechanism-of-action information.
Target maps can connect anticancer agents with proteins involved in tumor biology, helping researchers relate drug activity to candidate biomarkers. They can also show whether different compounds engage related or distinct targets and pathways. That information supports the design and interpretation of combination strategies, particularly when researchers seek complementary effects across signaling, DNA repair, or cell-cycle processes.